Therefore, a better understanding of the dysregulation of the antioxidant KEAP1-NRF2 activity in ALS could help to develop novel therapeutic strategies able to halt disease progression, prolonging patients’ survival. Here, KEAP1 is linked to amyotrophic lateral sclerosis.